<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Structure and current research status of some cyclophilin inhibitors.</p>
 </caption>
 <alt-text id="al0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name</th>
    <th>Structure</th>
    <th>Corporation</th>
    <th>Indication</th>
    <th>Activity</th>
    <th>Clinical trial stage</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>CsA</td>
    <td>
     <inline-graphic xlink:href="t1.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0015">Image 1</alt-text>
     </inline-graphic>
    </td>
    <td>Norvatis</td>
    <td>Adult, non-immunocompromised patients with severe, recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) and in patients for whom other systemic therapies are contraindicated or cannot be tolerated</td>
    <td>CsA inhibits the replication of many coronaviruses. Treatment of infected cells with 16 μM CsA strongly reduced viral and reporter gene expression of SARS-CoV–GFP, the amount of dsRNA in infected cells, and the viral titer in culture supernatants (by &gt;3 logs) [
     <xref rid="bb0165" ref-type="bibr">32</xref>].
    </td>
    <td>Indication mentioned previously: 
     <bold>On market</bold>
     <break/>Hepatitis C viral infection:
     <break/>
     <bold>Phase IV completed</bold>
    </td>
   </tr>
   <tr>
    <td>Alisporivir</td>
    <td>
     <inline-graphic xlink:href="t2.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0020">Image 2</alt-text>
     </inline-graphic>
    </td>
    <td>Norvatis</td>
    <td>Hepatitis C; chronic hepatitis C</td>
    <td>Alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with alisporivir and ribavirin increases the anti-MERS-CoV activity 
     <italic>in vitro</italic>
     <xref rid="bb0200" ref-type="bibr">[39]</xref>.
    </td>
    <td>Gastrointestinal disorders: 
     <bold>Preclinical</bold>
     <break/>Chronic hepatitis C virus infection/hepatitis C viral infection: 
     <bold>Phase III completed</bold>
    </td>
   </tr>
   <tr>
    <td>NIM811</td>
    <td>
     <inline-graphic xlink:href="t3.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0025">Image 3</alt-text>
     </inline-graphic>
    </td>
    <td>Novartis</td>
    <td>Hepatitis C; HIV-1 infection</td>
    <td>Induces a dose-dependent reduction of HCV RNA in the replicon cells with an IC50 of 0.66 μM at 48 h [
     <xref rid="bb0210" ref-type="bibr">40</xref>].
    </td>
    <td>Chronic hepatitis C genotype-1 relapse: 
     <bold>Phase II completed</bold>
    </td>
   </tr>
   <tr>
    <td>SCY-635</td>
    <td>
     <inline-graphic xlink:href="t4.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0030">Image 4</alt-text>
     </inline-graphic>
    </td>
    <td>SCYNEXIS, Inc.</td>
    <td>Hepatitis C; hepatitis B</td>
    <td>Show inhibition at 0.07, 0.08, and 0.15 μM, respectively, in the HCV subgenomic replicon system [
     <xref rid="bb0215" ref-type="bibr">41</xref>].
    </td>
    <td>Hepatitis C: 
     <bold>Phase II</bold>
     <break/>Hepatitis B: 
     <bold>No development reported</bold>
    </td>
   </tr>
   <tr>
    <td>STG-175</td>
    <td>
     <inline-graphic xlink:href="t5.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0035">Image 5</alt-text>
     </inline-graphic>
    </td>
    <td>S &amp; T Global</td>
    <td>Hepatitis B</td>
    <td>STG-175 inhibits at a nanomolar range the replication of all HCV genotypes: GT1a (EC50 = 13.5 nM), GT1b (EC50 = 15.1 nM), GT2a (EC50 = 11.5 nM), GT3a (EC50 = 38.9 nM) and GT4a (EC50 = 15.2 nM) [
     <xref rid="bb0220" ref-type="bibr">42</xref>].
    </td>
    <td>Hepatitis B: 
     <bold>Preclinical</bold>
    </td>
   </tr>
   <tr>
    <td>CRV431</td>
    <td>
     <inline-graphic xlink:href="t6.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0040">Image 6</alt-text>
     </inline-graphic>
     <break/>
    </td>
    <td>Hepion Pharmaceuticals</td>
    <td>Hepatitis B</td>
    <td>In a transgenic mouse model, CRV431 (10 mg/kg/day) reduced HBV DNA levels by only 13% relative to the vehicle group, the dose (50 mg/kg) reduced the mean HBV DNA level by 91% [
     <xref rid="bb0230" ref-type="bibr">44</xref>].
    </td>
    <td>Hepatitis B: 
     <bold>Phase I/II</bold>
     <break/>Hepatitis D; liver cancer; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis: 
     <bold>Preclinical</bold>
     <break/>Coronavirus infections; hepatitis C; HIV-1 infections: 
     <bold>Discontinued</bold>
    </td>
   </tr>
   <tr>
    <td>CPI-431-32</td>
    <td>
     <inline-graphic xlink:href="t7.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="al0045">Image 7</alt-text>
     </inline-graphic>
    </td>
    <td>Ciclofilin Pharmaceuticals Inc</td>
    <td>Hepatitis B</td>
    <td>Effectively inhibits HIV-1/HCV co-infection; also shows efficacy against drug-resistant HIV-1 and HCV variants. A daily CPI-431-32 dose of 0.5 μM is used. [
     <xref rid="bb0225" ref-type="bibr">43</xref>].
    </td>
    <td>Hepatitis B; neurological disorders; reperfusion injury:
     <break/>
     <bold>Preclinical-discontinued</bold>
     <break/>HIV-1, HCV: 
     <bold>Preclinical</bold>
     <break/>A study in healthy volunteers and patients with chronic hepatitis B:
     <break/>
     <bold>Phase I: Active, not recruiting</bold>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
